Sotac Pharmaceuticals Valuation
Is SOTAC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SOTAC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SOTAC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SOTAC's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SOTAC?
Key metric: As SOTAC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is SOTAC's PE Ratio? | |
|---|---|
| PE Ratio | 29.5x |
| Earnings | ₹44.60m |
| Market Cap | ₹1.32b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | 18.7x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does SOTAC's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 30.2x | ||
531398 Source Natural Foods and Herbal Supplements | 57.5x | n/a | ₹1.5b |
530233 Auro Laboratories | 19.6x | n/a | ₹1.2b |
524412 Aarey Drugs & Pharmaceuticals | 26.1x | n/a | ₹1.6b |
532637 Mangalam Drugs & Organics | 17.7x | n/a | ₹1.7b |
SOTAC Sotac Pharmaceuticals | 29.5x | n/a | ₹1.3b |
Price-To-Earnings vs Peers: SOTAC is good value based on its Price-To-Earnings Ratio (29.5x) compared to the peer average (30.2x).
Price to Earnings Ratio vs Industry
How does SOTAC's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
INDSWFTLAB Ind-Swift Laboratories | 1.6x | n/a | US$71.82m |
524652 Ind-Swift | 2x | n/a | US$13.29m |
| 2 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: SOTAC is good value based on its Price-To-Earnings Ratio (29.5x) compared to the Indian Pharmaceuticals industry average (32.2x).
Price to Earnings Ratio vs Fair Ratio
What is SOTAC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 29.5x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SOTAC's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Bal Pharma
₹2.2b
Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.
BALPHARMA
₹134.50
7D
11.6%
1Y
27.4%
Caplin Point Laboratories
₹147.7b
Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.
CAPLIPOINT
₹1,942.80
7D
-0.4%
1Y
58.1%
Venus Remedies
₹4.0b
Engages in the pharmaceutical business in India and internationally.
VENUSREM
₹298.65
7D
-1.3%
1Y
-16.9%